Date: 2015-01-11
Type of information: Distribution agreement
Compound:
Company: ArcherDX (USA - CO) Qiagen (The Netherlands)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism: Archer™ NGS utilizes best-in-class fusion detection technology with a lyophilized workflow and an advanced analysis pipeline to comprehensively detect fusions and mutations from as little as 10ng of nucleic acid. Using ArcherDX’s proprietary Anchored Multiplex PCR (AMP™) technology, researchers can detect and identify fusions without prior knowledge of fusion partners or breakpoints. Archer™ FusionPlex™ assays have been optimized for fusion and mutation detection and characterization, are FFPE compatible, and can run on both Illumina® and Ion Torrent™ next-generation sequencing platforms. Once sequenced, Archer FusionPlex libraries can be analyzed via the Archer Analysis Pipeline, a proprietary informatics analysis package that quickly detects and identifies fusion partners of assay genes as well as selected indels and point mutations.
Disease:
Details: * On January 11, 2015, ArcherDX, the NGS applications company, announced the formation of a new, independent company, which is focused on the development of the Archer™ line of next-generation sequencing (NGS) products. ArcherDX is the result of a business unit reorganization, in which Qiagen acquired the Enzyme Solutions Unit of Enzymatics, based in Beverly, Mass. ArcherDX integrates Enzymatics’ former Archer NGS and Supply Chain Solutions units. As part of the transaction, ArcherDX entered into a strategic partnership with Qiagen to distribute the company’s products. ArcherDX, which employs 87, is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass. The company’s chief executive, Dr. Myers, was the Chief Executive Officer of ArcherDX prior to its September 2013 acquisition by Enzymatics. Under Enzymatics, the ArcherDX team commercialized AMP™ technology, which addresses the bottlenecks associated with using next-generation sequencing in translational research. ArcherDX, which employs 87, is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass. The company’s chief executive, Dr. Myers, was the Chief Executive Officer of ArcherDX prior to its September 2013 acquisition by Enzymatics. Under Enzymatics, the ArcherDX team commercialized AMP™ technology, which addresses the bottlenecks associated with using next-generation sequencing in translational research. ArcherDX offers a best-in-class Archer FusionPlex™ product line of gene fusion assays, which utilize targeted enrichment chemistry and automated bioinformatic analysis to detect both known and novel fusions from RNA. The FusionPlex line of gene fusion assays include ALK, RET, ROS1; FGFR; NTRK; Heme; and Sarcoma panels, as well as a custom assay designer. “In the coming months, we look forward to launching a series of AMP™-based Universal DNA enrichment panels to complement our growing line of RNA panels,” added Dr. Myers.
Financial terms: Financial terms of the transactions are undisclosed.
Latest news:
